Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR 1,987.00
-14.10 (-0.70%)
Jul 31, 2026, 3:30 PM IST
NSE:SUNPHARMA Stock Forecast
Stock Price Forecast
According to 34 analysts polled by S&P Global, NSE:SUNPHARMA stock has a consensus rating of "Buy" and an average price target of ₹2,085. The average 1-year stock price forecast is 4.93% higher than the current stock price, while the lowest is ₹1,650 (-16.96%) and the highest is ₹2,366 (+19.07%).
Price Target: ₹2,085 (+4.93%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Feb 17, 2026.
Analyst Ratings
The average analyst rating for NSE:SUNPHARMA stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 24 | 23 | 22 | 20 | 20 | 20 |
| Buy | 9 | 9 | 7 | 10 | 10 | 10 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 2 | 2 | 1 | 1 | 1 | 1 |
| Total | 37 | 36 | 32 | 34 | 34 | 34 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Geojit Research No rating | Geojit Research | Buy Maintains ₹1,899 | Buy | Maintains | ₹1,899 | -4.43% | Feb 17, 2026 |
Financial Forecast
Revenue This Year
649.15B
from 584.62B
Increased by 11.04%
Revenue Next Year
730.80B
from 649.15B
Increased by 12.58%
EPS This Year
55.36
from 52.01
Increased by 6.43%
EPS Next Year
65.18
from 55.36
Increased by 17.75%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.